Vicor Technologies, Inc. (OTCBB: VCRT),
focused on commercializing its diagnostic risk stratification technology,
announced the U.S. National Institutes of Health (NIH), has selected Vicor
to present its proprietary risk stratification technology and scientific
findings at the 10th Annual NIH SBIR/STTR Conference, July 21-22, in
Atlanta, GA.
Vicor's abstract, "Risk Stratification for Arrhythmic Death in an Emergency
Room Department Cohort: A New Method of Nonlinear PD2i Analysis of the
ECG," will be presented during a NIH SBIR/STTR Scientific Poster Session.
This poster session also provides Vicor an opportunity to share information
with the scientific and business communities about recent advancements of
its risk stratification technology for triage of seriously injured military
or civilians in emergency situations.
NIH, a part of the U.S. Department of Health and Human Services, is the
primary Federal agency for conducting and supporting medical research,
anticipates over 800 conference attendees.
Vicor President and CEO Mr. David H. Fater stated, "Vicor is extremely
pleased to be selected as one of only 50 companies to present our
technology, and recent positive medical developments, at this prominent
National Institutes of Health conference. As Vicor commercializes its
technology, sessions such as this can be very important, and key, to
increasing Vicor's visibility and image within the medical, scientific and
business communities. In addition, it can provide the opportunity to meet
institutional researchers and corporations to promote strategic
relationships or collaborative activities -- such as our contract with the
U.S. Army."
About Vicor Technologies, Inc.
Vicor's diagnostic technology, currently being commercialized, is based on
a patented, proprietary algorithm for diagnostic risk stratification of
patients. Vicor believes its PD2i VS (Vital Sign) device will assist
physicians in triaging patients suffering from trauma and other critical,
serious injuries by identifying those who need immediate Life Saving
Intervention (LSI). Vicor is confident its second device, the PD2i Cardiac
Analyzer, accurately risk stratifies patients who are at high or low risk
of suffering a fatal arrhythmic event, or Sudden Cardiac Death (SCD),
within a six-month time frame.
In January 2008, the U.S. Army's Institute of Surgical Research and Vicor
signed a Collaborative Research and Development Agreement whereby the PD2i
will be utilized to assess severity of injury, and probability of survival,
for critically injured combat casualties and critically ill civilian
patients. The collaborative effort is envisioned to lead to the development
of new comprehensive decision support tools, and or devices that may
incorporate the PD2i algorithm alone, or in association with other metrics
currently under investigation, with the goal to monitor, assess status and
predict outcome in critically injured humans. The study is entitled
"Prediction of Injury Severity and Outcome in the Critically Ill Using the
Point Correlation Dimension Algorithm."
It is anticipated that U.S.
